Hexima’s Chief Science Officer, Professor Marilyn Anderson, Onychomycosis Project Leader, Dr Michael Baker and Researcher, Dr Brigitte Hayes, have presented Hexima’s human antifungal technology at ASM Microbe 2016. The conference is an opportunity to showcase the benefits of Hexima’s technology and our progress towards clinical trials for fungal nail infections (onychomycosis).  PhD Student Kathy Parisi also presented work relating to Hexima’s antifungal technology.

All three posters were met with an enthusiastic reception and generated significant interest among conference delegates.

Copies of the posters can be found below:

Sunday-391 – HXP124, a Plant Defensin, Represents a Novel Antifungal Therapeutic

Sunday-434 – HXP124 as a novel treatment for onychomycosis

Sunday-392 – Use of the Non-Essential Yeast Deletion Collection to Define the Antifungal Mechanisms of Plant Defensins

Prof Marilyn Anderson and Dr Michael Baker presenting Hexima's work at ASM Microbe 2016.

Prof Marilyn Anderson and Dr Michael Baker presenting Hexima’s work at ASM Microbe 2016.